Biotech entity
All 2 tracked stories fall under one category: pharma. Of the tracked stories, 2 of 2 also mention Citigroup, the most common co-covered peer. The 140-day window averages about 0.1 stories each week. Source depth averages 2 original sources per story, versus 3.4 across the same-window beat baseline.
Last mentioned: Aug 13, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 2 tracked stories fall under one category: pharma. Of the tracked stories, 2 of 2 also mention Citigroup, the most common co-covered peer. The 140-day window averages about 0.1 stories each week. Source depth averages 2 original sources per story, versus 3.4 across the same-window beat baseline. At 5, the average consequence score sits below the same-window beat average of 6.1. Wells Fargo & Company appears in 2 tracked Biotech stories published from February 21, 2026 through July 10, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 481 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Wells Fargo & Company. Shared-story counts are live from our verified record — not editorial picks.
Biotech and life sciences investors face a paradox: ResMed’s stalwart medical device business is underpinned by low debt and high margins, yet analyst targets range from $225 to $321 as GLP-1 therapies threaten its patient base.
Source: Ticker Report · Watch List News
Wells Fargo has upgraded AxoGen (NASDAQ: AXGN) to a 'Strong-Buy' rating, reflecting growing institutional confidence in the company's leadership in peripheral nerve repair. The upgrade follows a significant price target increase from Jefferies and a reaffirmed 'Market Outperform' rating from Citigroup.
Wells Fargo & Company is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
